Clinical Trials | May 26, 2026
Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy
A one-shot gene-editing cholesterol therapy could soon be a reality
A one-shot gene-editing cholesterol therapy could soon be a reality
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
With standout ADC and t-cell engager response data across hard-to-treat cancers
Clearance marks major shift beyond chemotherapy
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The decision marks a key step in the centralized EU review process
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Subscribe To Our Newsletter & Stay Updated
